To explore the efficacy of the cell-based therapy of IFNα-AF-MSCs, AF-MSCs (n = 12) or IFNα-AF-MSCs (n = 15) were administered intravenously (i.v.)into the tail veins of tumor-bearing mice. This evidence concerns the gene IFNA1 and neoplasm.